{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462798006
| IUPAC_name = 1-(4-Methylphenyl)-3-azabicyclo[3.1.0]hexane
| image = Bicifadine.svg
| width = 170

<!--Clinical data-->
| tradename = 
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category = 
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = Unscheduled
| legal_status = 
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 1.6 hours
| excretion = renal

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 71195-57-8
| ATC_prefix = none
| ATC_suffix = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 511099
| PubChem = 47953
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = B0SV3N7J3H
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9889978
| smiles = c1cc(ccc1C)[C@]32CNC[C@@H]2C3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H15N/c1-9-2-4-10(5-3-9)12-6-11(12)7-13-8-12/h2-5,11,13H,6-8H2,1H3/t11-,12+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OFYVIGTWSQPCLF-NWDGAFQWSA-N

<!--Chemical data-->
| C=12 | H=15 | N=1 
| molecular_weight = 173.25 g/mol
| melting_point = 
| melting_high = 
}}

'''Bicifadine''' ('''DOV-220,075''') is a [[serotonin-norepinephrine-dopamine reuptake inhibitor]] (SNDRI) discovered at [[American Cyanamid]] as an [[analgesic]] drug candidate, and licensed to [[DOV Pharmaceutical]] in 1998 after American Cyanamid was acquired by [[Wyeth]].<ref name=Marks>Marks DM, Pae CU, Patkar AA.  Triple reuptake inhibitors: a premise and promise. Psychiatry Investig. 2008 Sep;5(3):142-7. {{PMID|20046357}} {{PMC|2796030}}</ref><ref>[https://www.sec.gov/Archives/edgar/data/1066833/000114420404018172/v08017_ex10-51.txt SEC Filing: Wyeth-DOV Restated License Agreement] Page accessed July 15, 2015]</ref><ref name=Neubauer>Neubauer, DN.  "Indiplon". pp 453-464 in GABA and Sleep: Molecular, Functional and Clinical Aspects.  Eds Jaime M. Monti, Seithikurippu Ratnas Pandi-Perumal, Hanns Möhler.  Springer Science & Business Media, 2010 {{ISBN|9783034602266}}</ref>

In January 2007, Dov licensed the rights to bicifadine to XTL Biopharmaceuticals after bicifadine failed in a Phase III clinical trial for chronic lower back pain.<ref>BioCentury, July 26, 2010 {{full citation needed|date=July 2017}}</ref><ref>{{cite web | url = http://euthymics.com/wp-content/uploads/2011/12/EUTHYMICS_BIOSCIENCE_ECP_BERNSTEIN_REPORT_120511bc1.pdf | title = Euthymics: Balancing act | page = A13 | publisher = BioCentury, The Bernstein Report on Biobusiness | date = December 5, 2011}}</ref><ref>John Caroll for Fierce Biotech. Jan 07, 2007 [http://www.fiercebiotech.com/story/xtl-licenses-development-rights-to-pain-therapy/2007-01-16 XTL licenses development rights to pain therapy]</ref> XTL ran a PhaseIIb clinical trial for pain caused by [[diabetic neuropathy]], which failed in 2008;<ref>Fierce Biotech. December 9, 2008  [http://www.fiercebiotech.com/story/tiny-xtl-cuts-costs-jobs/2008-12-09 Tiny XTL cuts costs, jobs]</ref>  XTL terminated the agreement in 2010.<ref>[http://markets.on.nytimes.com/research/stocks/fundamentals/drawFiling.asp?docKey=137-000114420413017126-72672IPVQ4UFBUKR6AA4FI0HPE&docFormat=HTM&formType=6-K XTL Form 6-K March, 2013]</ref>  In 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of other candidates from Dov's portfolio.<ref>Fierce Biotech July 22, 2010 [http://www.fiercebiotech.com/story/euthymics-lands-24m-fund-antidepressant-work/2010-07-22 Euthymics lands $24M to fund antidepressant work]</ref>

Bicifadine has a non-[[opioid]], non-[[NSAID]] [[mechanism of action|mechanism]] for the treatment of pain, which should have less abuse potential than opioid drugs and less propensity to cause gastric ulcers than NSAID drugs.<ref name=Wang>{{Cite journal 
| last1 = Wang | first1 = R. I. 
| last2 = Johnson | first2 = R. P. 
| last3 = Lee | first3 = J. C. 
| last4 = Waite | first4 = E. M. 
| title = The Oral Analgesic Efficacy of Bicifadine Hydrochloride in Postoperative Pain 
| journal = Journal of Clinical Pharmacology 
| volume = 22 
| issue = 4 
| pages = 160–164 
| year = 1982 
| pmid = 7096604 | doi=10.1002/j.1552-4604.1982.tb02157.x
}}</ref> While the drug is purported to be a [[serotonin transporter|serotonin]] (SERT) and [[noradrenaline transporter]] (NET) inhibitor, it also has effects at the [[dopamine transporter]] (DAT), effectively making it a broad-spectrum monoamine transporter inhibitor or "[[triple reuptake inhibitor]]."<ref name=Basile>{{Cite journal
| last1 = Basile | first1 = A.
| last2 = Janowsky | first2 = A.
| last3 = Golembiowska | first3 = K.
| last4 = Kowalska | first4 = M.
| last5 = Tam | first5 = E.
| last6 = Benveniste | first6 = M.
| last7 = Popik | first7 = P.
| last8 = Nikiforuk | first8 = A.
| last9 = Krawczyk | first9 = M.
| last10 = Nowak | first10 = G.
| last11 = Krieter | first11 = P. A.
| last12 = Lippa | first12 = A. S.
| last13 = Skolnick | first13 = P.
| last14 = Koustova | first14 = E.
| title = Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain
| journal = The Journal of Pharmacology and Experimental Therapeutics
| volume = 321
| issue = 3
| pages = 1208–1225
| year = 2007
| pmid = 17325229
| doi = 10.1124/jpet.106.116483
}}</ref>

==See also==
* [[DOV-216,303]]

== References ==
{{reflist}}

{{Analgesics}}
{{Antidepressants}}
{{Monoamine reuptake inhibitors}}

[[Category:Abandoned drugs]]
[[Category:Analgesics]]
[[Category:Cyclopropanes]]
[[Category:Pyrrolidines]]
[[Category:Serotonin-norepinephrine-dopamine reuptake inhibitors]]